A new neo-lignan from culture broth of Phellinus linteus and its dengue virus type-2 inhibition activity

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2024-08-08 DOI:10.1016/j.phytol.2024.08.005

Young-Hee Kim , Dae-Cheol Choi , Dae-Won Ki , Ji-Yul Kim , Jae-Hyoung Song , Hyun-Jeong Ko , In-Kyoung Lee , Bong-Sik Yun

引用次数: 0

Abstract

Several species within the genus Phellinus are used as a traditional medicine for various health conditions. A new neo-lignan derivative, phelignan A (1), and a known neo-lignan (2) were isolated from the culture broth of P. linteus. The chemical structures of the isolated compounds were determined using 1D- and 2D-NMR and MS data and by comparisons of the data with those reported in the literature. The anti-viral activity of the isolated compounds against dengue virus-2 (DENV-2) was evaluated. Compounds 1 and 2 exhibited anti-viral activity against DENV-2, with IC₅₀ values of 1.45 and 2.15 µM, respectively.

查看原文本刊更多论文

黄柏培养液中的一种新木质素及其对登革热病毒 2 型的抑制活性

该属的几个物种被用作治疗各种健康问题的传统药物。从......的培养液中分离出了一种新的新木质素衍生物--helignan A（）和一种已知的新木质素（）。利用一维和二维核磁共振和质谱数据，并通过与文献报道的数据进行比较，确定了所分离化合物的化学结构。评估了分离化合物对登革病毒-2（DENV-2）的抗病毒活性。化合物和化合物对 DENV-2 具有抗病毒活性，IC 值分别为 1.45 和 2.15 µM。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.